BOSTON, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. (OTCQB: BIXT) today announced positive clinical results from its recently completed Phase 2 randomized, double-blind, placebo-controlled, dose-optimization trial evaluating ProLectin-M in subjects with laboratory-confirmed acute viral infection. The Bioxyytran Trial reports complete elimination of viral load in 100% of patients at day 7 versus placebo (p=.001). The completed Phase 2 clinical study was a randomized, double-blind, placebo-controlled, ...

BOSTON, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. (OTCQB: BIXT) today announced positive clinical results from its recently completed Phase 2 randomized, double-blind, placebo-controlled, dose-optimization trial evaluating ProLectin-M in subjects with laboratory-confirmed acute viral infection. The Bioxyytran Trial reports complete elimination of viral load in 100% of patients at day 7 versus placebo (p=.001). The completed Phase 2 clinical study was a randomized, double-blind, placebo-controlled, ...

Core Insights - Bioxytran, Inc. is making significant progress in the development of its antiviral drug ProLectin-M, which is currently under an active Investigational New Drug (IND) application with the FDA [1] - ProLectin-M targets the galectin fold on spike proteins of various viruses, including SARS-CoV-2, influenza, and RSV, demonstrating high efficacy in clinical trials [2] - The drug's development aligns with a shift in U.S. health policy, creating a unique opportunity for Bioxytran as resources are redirected away from mRNA vaccines [3] Company Overview - Bioxytran is focused on developing linear complex carbohydrate-based therapeutics to address unmet medical needs in virology, cancer metastasis, and oxygen transport [5] - The company is advancing multiple programs, including ProLectin-M and a stroke treatment program utilizing an FDA-approved device [5] Research and Development - ProLectin-M has shown a complete response in clinical trials, with negative PCR tests in all subjects by day 7 and an 88% response rate by day 3 [2] - The drug's mechanism involves blocking galectins to prevent viral attachment to host cells, with ongoing research into its efficacy against other viruses like Epstein-Barr Virus [4]

Core Insights - Bioxytran, Inc. is making significant progress in the development of its antiviral drug ProLectin-M, which is currently under an Investigational New Drug (IND) application with the FDA [1] - ProLectin-M targets the galectin fold on spike proteins of various viruses, including SARS-CoV-2, influenza, and RSV, demonstrating high efficacy in clinical trials [2] - The drug's development aligns with a shift in U.S. health policy, potentially positioning ProLectin-M as a first-line therapy for respiratory infections [3] Development Progress - The company has completed dosing in its dose optimization clinical trial, marking a critical milestone in refining the drug's dosing strategy [1][2] - ProLectin-M has shown a complete response in all subjects by day 7 and an 88% response rate by day 3 in double-blind placebo-controlled trials [2] Technology and Mechanism - Bioxytran's platform utilizes linear complex carbohydrate structures to block galectins, which are proteins that facilitate viral attachment to host cells [4] - Ongoing research is exploring ProLectin-M's efficacy against other viruses, including Epstein-Barr Virus (EBV) [4] Strategic Positioning - The company believes that the redirection of resources away from mRNA vaccines creates a unique opportunity for ProLectin-M to become a first-line therapy for patients without underlying medical conditions [3] - Bioxytran is also advancing other therapeutic programs, including those for stroke treatment, leveraging its proprietary technologies [5]